All In Biotech

Drug Trial Radar · NCT07595874

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Dec 16, 2028

Study completion Dec 16, 2028

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that can be removed by surgery (resectable) colorectal cancer. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab before surgery may make the tumor smaller. Giving neoadjuvant botensilimab and balstilimab may be effective for the treatment of advanced resectable colorectal cancer.

Conditions

  • Advanced Colon Adenocarcinoma
  • Advanced Colorectal Adenocarcinoma
  • Advanced Rectal Adenocarcinoma
  • Stage IIB Colon Cancer AJCC v8
  • Stage IIB Rectal Cancer AJCC v8
  • Stage IIC Colon Cancer AJCC v8
  • Stage IIC Rectal Cancer AJCC v8
  • Stage IIIA Colon Cancer AJCC v8
  • Stage IIIA Rectal Cancer AJCC v8
  • Stage IIIB Colon Cancer AJCC v8
  • Stage IIIB Rectal Cancer AJCC v8
  • Stage IIIC Colon Cancer AJCC v8
  • Stage IIIC Rectal Cancer AJCC v8

Interventions

  • BalstilimabBiological

    Given IV

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • BotensilimabBiological

    Given IV

  • Computed TomographyProcedure

    Undergo CT scan

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Two-year disease-free survival rateTime frame: At 2 years post enrollment

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona · Recruiting

  • City of Hope Corona

    Corona, California · Recruiting

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • City of Hope Seacliff

    Huntington Beach, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • City of Hope at Long Beach Elm

    Long Beach, California · Recruiting

  • City of Hope South Pasadena

    South Pasadena, California · Recruiting

  • City of Hope Upland

    Upland, California · Recruiting

  • City of Hope Atlanta Cancer Center

    Newnan, Georgia · Recruiting

  • City of Hope at Illinois Chicago Downtown

    Chicago, Illinois · Recruiting

  • City of Hope at Chicago

    Zion, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.